On September 1, 2026, Edge Medical® received medical device registration approval from Türkiye’s Medicines and Medical Devices Agency (TİTCK) for three core products:

✅ Edge® Multi-port Endoscopic Surgical Robot MP1000

✅ Edge® Single-port Endoscopic Surgical Robot SP1000

✅ Edge® Multi/Single-port Robotic Surgical Super System MSP2000

These platforms cover urology, gynecology, general surgery, and thoracic surgery—giving hospitals flexible options across multi-port, single-port, and integrated robotic approaches.

Why Türkiye matters

Türkiye sits at the crossroads of Europe, the Middle East, and surrounding markets. Its medical device regulations are highly aligned with EU MDR, and its healthcare system has growing demand for high-end technologies, including robotic-assisted surgery. The market relies heavily on imports for advanced medical devices, making it a key strategic hub for international medtech companies.

Building on global regulatory momentum

This approval follows existing certifications including China NMPA, EU CE, Brazil ANVISA, and Australia TGA. It reflects Edge Medical®’s growing capabilities in R&D, quality management, clinical validation, and international regulatory affairs.

What this means for hospitals and surgeons

With the full product matrix now approved in Türkiye, healthcare institutions can choose the right robotic platform based on department structure, clinical needs, procedural characteristics, and stage of robotic program development. From multi-port to single-port to integrated systems, we’re expanding the boundaries of robotic surgery in real-world clinical settings.

Edge Medical® is committed to deepening local clinical application and commercialization in Türkiye—and using this Eurasian foothold to accelerate broader global adoption.